Nishkantha Arulkumaran

Clinical review: Goal-directed therapy-what is the evidence in surgical patients? The effect on different risk groups

Maurizio Cecconi, Carlos Corredor, Nishkantha Arulkumaran et al. · Critical Care · 2012 · 348 citations · Full text

Medicine, Perioperative Medicine, Surgery +17

Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients

Stephen P. McAdoo, Anisha Tanna, Zdenka Hrušková et al. · Kidney International · 2017 · 236 citations · Full text

Life Sciences, Immunology, Nephrology +17

Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study

Nishkantha Arulkumaran, N. Periselneris, G. Gaskin et al. · Lara D. Veeken · 2011 · 136 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +14

Priorities for Future Intensive Care Research in the UK: Results of a James Lind Alliance Priority Setting Partnership

Hannah Reay, Nishkantha Arulkumaran, Stephen J. Brett · Journal of the Intensive Care Society · 2014 · 87 citations · Full text

Medicine, Clinical Sciences, Critical Care Medicine +12

Is the inflammasome a potential therapeutic target in renal disease?

Clare M. Turner, Nishkantha Arulkumaran, Mervyn Singer et al. · BMC Nephrology · 2014 · 86 citations · Full text

Medicine, Immunology, Pathology +17